ID: ALA418018

Max Phase: Preclinical

Molecular Formula: C30H22N4O

Molecular Weight: 454.53

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cn1cncc1C(O)(C#Cc1cccc(N)c1)c1ccc(C#N)c(-c2cccc3ccccc23)c1

Standard InChI:  InChI=1S/C30H22N4O/c1-34-20-33-19-29(34)30(35,15-14-21-6-4-9-25(32)16-21)24-13-12-23(18-31)28(17-24)27-11-5-8-22-7-2-3-10-26(22)27/h2-13,16-17,19-20,35H,32H2,1H3

Standard InChI Key:  ZPHPMNJCCXXCGX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 454.53

Molecular Weight (Monoisotopic): 454.1794

AlogP: 4.98

#Rotatable Bonds: 3

Polar Surface Area: 87.86

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.18

CX Basic pKa: 5.87

CX LogP: 4.66

CX LogD: 4.65

Aromatic Rings: 5

Heavy Atoms: 35

QED Weighted: 0.30

Np Likeness Score: -0.75

References

1. Lin NH, Wang L, Cohen J, Gu WZ, Frost D, Zhang H, Rosenberg S, Sham H..  (2003)  Synthesis and biological evaluation of 4-[3-biphenyl-2-yl-1-hydroxy-1-(3-methyl-3H-imidazol-4-yl)-prop-2-ynyl]-1-yl-benzonitrile as novel farnesyltransferase inhibitor.,  13  (7): [PMID:12657267] [10.1016/s0960-894x(03)00122-7]

Source

Source(1):

• Scientific Literature